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Background: Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) can 
signiﬁ cantly decrease cardiovascular mortality and morbidity, irrespective of the patients’ 
cholesterol status. This paper reviews the effects of perioperative statin therapy in patients 
undergoing noncardiac surgery.
Method: A systematic literature review was undertaken of all published literature on this 
subject using Medline and cross-referenced. All published relevant papers on the perioperative 
use of statins were used.
Results: Perioperative statin therapy is associated with a lower perioperative morbidity and 
mortality in patients undergoing elective or emergency surgery. The effects are due to a com-
bination of lipid-lowering and pleiotropic properties of statins.
Conclusion: Ideally a large scale multi-centre randomized controlled trial of perioperative 
statin therapy should be performed but this may be difﬁ cult to conduct since there is already 
overwhelming evidence in the literature to suggest perioperative cardiovascular protective 
properties. Statins may still be under-prescribed in surgical patients.
Keywords: perioperative, cardiac complications, morbidity, mortality, outcome, statins, vas-
cular, noncardiac surgery
Perioperative cardiac complications
Cardiac complications are a major cause of perioperative and late morbidity and 
mortality, especially in patients undergoing vascular surgery (Priebe 2004). This 
is particularly related to underlying ischemic heart disease, which is frequently 
asymptomatic and the prevalence of which is increasing in many countries. Since the risk 
factors for coronary artery disease and peripheral vascular disease are the same, patients 
undergoing vascular surgical procedures are at particularly high risk in developing 
perioperative cardiac complications (Ashton et al 1993; Kertai et al 2006). A recent 
Vascular Anaesthesia Society audit identiﬁ ed a perioperative mortality rate of 7.3% in 
patients undergoing infrarenal aortic surgery with most of these deaths attributable to 
cardiac events (Bayly et al 2001). Unfortunately despite an improvement in the safety 
of modern anesthesia, better drugs and advances in perioperative patient monitoring, 
the mortality from myocardial infarction after noncardiac surgery is still high, and is 
believed to be 10% to 15% (Adesanya et al 2006). In a cohort of 323 patients with 
a cardiac history who underwent noncardiac surgery, Badner and colleagues (1998) 
showed that 18 (5.6%) patients developed postoperative myocardial infarction with 
electrocardiogram and enzyme (creatinine kinase and troponin-T) changes, but only 3 
of these were clinically apparent with central chest pain. In this cohort of patients, the 
great majority of myocardial infarctions occurred within the ﬁ rst 3 days postoperatively 
(Badner et al 1998). It may be difﬁ cult to assess the true incidence of postoperative 
myocardial infarction, as it is dependent on the speciﬁ city and sensitivity of the 
method of diagnosis (Gibson et al 2007), and the fact that some are silent clinically 
(Pasternack et al 1989). In a prospective study involving 444 patients with or at high 
risk for coronary artery disease who underwent elective noncardiac surgery, Mangano 
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and colleagues (1992) found that postoperative myocardial 
ischemia increased the odds for long-term (30 days to 
2 years after surgery) cardiac events (unstable angina, nonfatal 
myocardial infarction, cardiac death, surgical coronary 
revascularization) by 2.2-fold. Timing of surgery following 
myocardial infarction has some importance, although risk is 
related more to the functional status of the ventricles than
time period since the myocardial infarction. At less than 
6 weeks the risk is relatively high as the damaged myocardium 
is still healing. There appears then to be an intermediate risk 
period up to 3 months but, in uncomplicated cases, no beneﬁ t 
in delaying surgery beyond this (Eagle et al 1997).
The pathophysiology of reversible myocardial ischemia or 
perioperative myocardial infarction is not entirely clear, and is 
likely to be multifactorial. The main cause is due to rupturing 
of the unstable coronary atherosclerotic plaque, leading to 
thrombus formation, arterial stenosis and occlusion, ischemia 
of the cardiac muscle which may subsequently lead to 
myocardial infarction if this is prolonged (Priebe 2004; Cohen 
and Aretz 1999; Zaman et al 2000; Schouten et al 2006a). 
Surgical stress imposes extra myocardial workload due to 
local and systemic effects, such as perioperative blood loss, 
tachycardia, induction of catecholamines and glucocorticoids, 
tachycardia, blood pressure lability and pain. Patients with 
cardiac disease are particularly susceptible and since many 
of these patients are not symptomatic, it is important to try to 
identify those at risk and institute risk reduction strategies.
Careful preoperative evaluation can help to determine 
patients at particular risk, although many costly, potentially 
hazardous cardiac investigations are probably unnecessary 
and have poor predictive value. In a study of 32 patients 
who died within 30 days of vascular surgery, only half 
had evidence of ischemia on dobutamine stress echocar-
diography; and in 36% of the patients dobutamine stress 
echocardiogram did not predict the location of the infarct 
(Poldermans et al 2001). Many of the proposed surgeries are 
urgent and it may not be appropriate to undertake coronary 
revascularization. Furthermore there is increasing evidence 
that percutaneous coronary angioplasty and stenting may 
not be helpful in many patients (Boden et al 2007) and even 
place some at higher risk. This is probably because risk of 
myocardial infarction is related more to atheromatous plaque 
stability than degree of stenosis (Abram 2005). Consequently 
we should probably be less stringent in our criteria for 
identifying high risk patients and improvement of outcome 
is most likely using medical therapy to control heart rate and 
blood pressure, reduce inﬂ ammation, and stabilize coronary 
atheromatous plaques.
Beta blockers induce a shift from free fatty acids 
toward glucose as the main cardiac energy substrate, thus 
resulting in an improved energy efﬁ ciency and outcome; 
possess an antiarrhythmic effect and antirenin/angiotensin 
properties; and have antiinﬂ ammatory qualities. In addition, 
beta-blockade might blunt the adrenergic surge and reduce 
the adverse outcomes during surgery. A combination of 
beta blockers, low dose aspirin and statins is currently 
most promising and a number of large clinical trials have 
been looking at these treatments (Devereaux et al 2005). 
Statins may also reduce the incidence of stroke after carotid 
endarterectomy, contrast-induced nephropathy, improve graft 
survival, and appear to have a good safety proﬁ le. Currently 
statins are probably the most promising group of drugs in 
this perioperative setting (Biccard et al 2005).
The cardiovascular protective 
properties of statins
Atherosclerosis is a multi-factorial systemic disease, with 
hyperlipidemia as an important risk factor. For more than 
a decade, statins have been used clinically in lowering 
elevated levels of cholesterol and thus decreasing the risk for 
atherosclerosis (Grundy 1988; Eisenberg 1998; Ashen and 
Blumenthal 2005). Not only are statins highly effective in 
reducing low-density lipoproteins and cholesterol, they also 
increase high-density lipoproteins and have additional beneﬁ cial 
effects on systemic atherosclerosis. Statins have pleiotropic 
effects which improve or restore endothelial function, and can 
stabilize the atherosclerotic plaques by decreasing oxidative 
stress and vascular inﬂ ammation (Takemoto and Liao 2001; 
Libby 2002; Liao 2005) (Table 1).
Large multi-centre randomized controlled trials have 
consistently shown that statins are safe and effective in 
reducing low-density lipoprotein cholesterol and beneﬁ cial 
in the primary and secondary prevention of coronary heart 
Table 1 Effects of statins
Lipid lowering effects
• decrease cholesterol
• increase HDL
Pleiotropic effects
• increase endothelial NO synthetase
• generation of ROS
• decrease endothelin-1 production
• improve thrombogenic profi le
• decrease Infl ammation (decrease isoprenoid production)
• decrease CRP levels
• inhibition of atherosclerosis
Abberviations: CRP, C-reactive protein; HDL, high-density lipoprotein; NO, nitric 
oxide; ROS, reactive oxygen species.
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disease. Between 1994 and 1997, three major trials – the 
Scandinavian Simvastatin Survival Study (4S 1994), the 
CARE (Cholesterol and Recurrent Events) Trial (Sacks 
et al 1996) and the LIPID (Long-term Intervention with 
Pravastatin in Ischemic Disease) Study Group (1998) have 
all showed that simvastatin and pravastatin reduced the risk 
of a recurrent coronary event in patients with established 
coronary heart disease. The results of CARE and LIPID, 
with pravastatin, also showed that the beneﬁ ts of improved 
survival extended to the majority of patients with coronary 
heart disease irrespective of their serum cholesterol levels. 
Since then, further studies including the MRC/BHF Heart 
Protection Study (Heart Protection Study Collaborative 
Group 2002), the ALLHAT Trial (2002), and the PROSPER 
Trials (Shepherd et al 2002) have also reiterated the same 
conclusion that statins are beneﬁ cial to patients with coronary 
atherosclerosis, irrespective of their cholesterol levels.
Perioperative use of statins
There are many studies involving a large number of patients to 
show that perioperative statin use is beneﬁ cial. Perioperative 
statin therapy has been shown to improve short and long-term 
patient outcome following cardiac and noncardiac surgery 
(Hindler et al 2006b). With no clinical studies reporting an 
increased incidence of adverse effects of perioperative statin 
use, it appears to be a safe and efﬁ cacious therapeutic option 
(Dunkelgrun 2006).
In a randomized, double-blind, placebo-controlled trial 
involving 6605 patients receiving a low-saturated fat, low-
cholesterol diet, Downs and colleagues (1998) showed that 
lovastatin (20–40 mg daily) reduced the risk for the fatal or 
nonfatal myocardial infarction, unstable angina, or sudden 
cardiac death. In prospectively collected data from 1993 
to 1999 involving 5052 patients undergoing percutaneous 
coronary angioplasty or stenting, Chan and colleagues (2002) 
showed that only 26.5% of the patients were treated with 
statins, and statin therapy was associated with a statistically 
signiﬁ cant mortality reduction at 30 days and 6 months 
after coronary intervention. This study was conducted in the 
1990s, and it is likely that the number of patients receiving 
statin therapy is much higher nowadays. Long-term statin 
administration was associated with a reduced incidence of 
adverse cardiovascular outcomes and a decreased need for 
coronary artery bypass graft (Chan et al 2002).
Lindenauer and colleagues (2004) performed a retrospec-
tive cohort study for a 2 year period from 2000 using data 
from 329 hospitals throughout the United States involving 
780,591 patients who underwent major noncardiac surgery. 
In this study, the overall perioperative mortality rate was 
2.96%, and, despite the fact that the patients on statin therapy 
were older, had a higher number of comorbidities, and a 
higher revised cardiac risk index score than those patients 
who were not treated, the use of statins during the early peri-
operative period was associated with a 1% absolute reduction 
of hospital mortality and a 38% reduction in the odds of in-
hospital mortality among patients undergoing major noncar-
diac surgery (Lindenaur et al 2004). Similarly, in a 10 year 
retrospective case-controlled study involving 2816 patients 
who underwent major vascular surgery between 1991 and 
2000, Poldermans et al found that the risk of perioperative 
mortality among statin users was reduced 4.5 times compared 
with nonusers. This reduction in mortality was consistent in 
subgroup analysis independent of the type of surgery, cardiac 
risk factors, and cardiovascular therapy, including aspirin 
and β-blockers (Poldermans et al 2003). Similar conclusions 
were reached by Noordzij and colleagues (2007) in a case-
controlled study in 75,581 patients who underwent 108,593 
noncardiac, nonvascular surgical procedures over a 10 year 
period between 1991 and 2001, statins were associated with 
a 60% mortality reduction.
In a prospective, randomized, placebo-controlled, double-
blind clinical trial involving 100 eligible consecutive patients 
scheduled for elective noncardiac vascular surgery in Brazil, 
Durazzo and colleagues (2004) found that patients taking 
atorvastatin had a statistically signiﬁ cant reduced rate of 
cardiac events within 6 months after surgery. In another 
study examining the effects of different types of statins 
(simvastatin, ﬂ uvastatin, pravastatin, and atorvastatin) in 211 
consecutive patients who underwent major elective vascular 
surgery between 1998 and 2004, Schouten and colleagues 
(2005) found that statins were well tolerated and patients on 
statins had a more favorable perioperative cardiac outcome. 
In a 14-year period study involving 511 patients with left 
ventricular dysfunction undergoing noncardiac vascular sur-
gery, Feringa and colleagues (2007) found that statins were 
signiﬁ cantly and independently associated with a reduced 
incidence of in-hospital cardiac related mortality. The same 
authors found in a cohort of 1374 patients with peripheral 
arterial disease that long term high dose statin therapy was 
associated with an improved outcome both in mortality and 
cardiac morbidity, irrespective of whether the patients had 
surgery or not (Feringa et al 2007).
Perioperative statin therapy is also associated with 
favorable perioperative outcomes unique to vascular surgery. 
Schouten and colleagues (2006c) showed that statin use 
can reduce the rate of growth of infrarenal aortic aneurysm, 
Vascular Health and Risk Management 2008:4(1)78
Chan et al
although better blood pressure control in statin users in this 
study could have been a contributing factor as signiﬁ cantly 
more statin users were on angiotensin-II-antagonist therapy. 
In a retrospective study involving 510 patients with a 
median follow-up period of 4.7 years, Kertai and colleagues 
(2004) showed that patients receiving both statins and beta-
blockers had a four fold reduction in perioperative mortality 
and nonfatal myocardial infarction after abdominal aortic 
aneurysm surgery, compared with patients receiving statins 
alone. In a retrospective review of 446 patients who underwent 
infrainguinal vascular bypass with a mean follow-up period of 
5.5 years, Ward and colleagues (2005) found that preoperative 
statin therapy was associated with less perioperative cardiac 
and major vascular complications, a shorter length of stay, and 
improved long-term survival. The ﬁ ndings of these studies are 
similar to the conclusion from the Statins for Risk Reduction 
in Surgery (StaRRS) study, a retrospective study with 
1163 patients in which perioperative statin therapy was shown 
to have a highly signiﬁ cant myocardial protective effect in 
vascular patients, irrespective of their cholesterol levels 
(O’Neil-Callahan et al 2005). In addition, perioperative statin 
therapy appeared to have a renal protective effect in patients 
undergoing complex aortic surgery. In 77 patients with normal 
preoperative renal function requiring suprarenal aortic cross 
clamping-declamping during vascular surgery, Schouten 
and colleagues (2006b) showed that postoperative creatinine 
levels during the 30 days after surgery were signiﬁ cantly lower 
in statin users than in nonusers, and temporary postoperative 
hemodialysis was required in 7 patients, all of whom were 
not on perioperative statin therapy. There is an increasing 
trend towards endovascular surgery and this may involve the 
use of large amounts of contrast media with implications for 
renal function. A study of patients undergoing percutaneous 
coronary interventions found that pre-procedure statin use 
was associated with signiﬁ cant reduction in contrast induced 
nephropathy (Khanal et al 2005), although this effect is more 
controversial (Wong and Irwin 2007). In two recent review 
articles, the authors concluded that perioperative statin use in 
high-risk patients undergoing major elective vascular surgery 
is beneﬁ cial and safe, although the dosage and duration of 
treatment remained undeﬁ ned (Boushra and Muntazar 2006; 
Paraskevas et al 2006).
In a study involving 98 patients who underwent carotid 
endarterectomy, of whom 43 (44%) were on statin treatment 
at least 3 months before endarterectomy and 55 (56%) had 
never received statin treatment, Koutouzis and colleagues 
(2007) showed that perioperative statin therapy was 
beneﬁ cial in that it was associated with reduced intraplaque 
angiogenesis in the carotid arteries. Intraplaque angiogenesis 
can cause progression of atherosclerotic plaque and also lead 
to plaque instability and rupture (Imparato et al 1983). The 
pathophysiology can be applied clinically as intraplaque 
angiogenesis and vascularization of the carotid plaque 
can cause ipsilateral neurological symptoms within one 
month of the surgical procedure and with perioperative and 
intraoperative evidence of distal embolization (McCarthy 
et al 1999). Poldermans and colleagues (2003) showed that 
statin use reduces perioperative cardiac and cerebrovascular 
mortality in patients undergoing major vascular surgery. 
Long term post-operative statin therapy is also beneﬁ cial as 
statins can enhance the rate of apoptosis in neointimal smooth 
muscle cells and reduce,the rate of myointimal hyperplasia 
and restenosis (Erl et al 2003). In a single centre study 
of 2127 primary carotid endarterectomy in 1853 patients 
between 1989 and 1999, LaMuraglia and colleagues (1995) 
have shown that lipid-lowering therapy is protective against 
carotid re-stenosis, and had favorable effects on patient 
survival.
In a retrospective analysis of 172 consecutive patients 
who underwent primary autogenous infrainguinal reconstruc-
tions with long saphenous vein, Abbruzzese and colleagues 
(2004) showed that statin therapy had a beneﬁ cial effect on 
graft patency in a follow-up period of two years. The patients 
on perioperative statin therapy had a much lower incidence of 
graft occlusions (Abbruzzese et al 2004). In 293 patients who 
had infrainguinal bypass grafts with either autologous vein 
or prosthetic conduits, Henke and colleagues (2004) showed 
that patients on statins have an improved graft patency rate, 
a decreased amputation rate and shorter in-hospital length 
of stay (Ward et al 2005). Higher doses of statins have addi-
tional advantage in patients with peripheral arterial disease 
(Feringa et al 2007).
Contrary to the peri-operative use of statins, Podermans 
and colleagues (2007) showed in a randomized trial that 
preoperative coronary revascularization in high-risk patients 
was not associated with an improved outcome. In order to 
determine the effect of statin therapy in perioperative cardiac 
complications and mortality in patients undergoing coronary 
artery bypass grafts, Collard and colleagues (2006) showed 
in 2666 randomized patients that preoperative statin therapy 
was associated with a statistically signiﬁ cant reduction in 
the risk of early cardiac related mortality. Statins did not 
reduce the risk of early postoperative nonfatal early cardiac 
complications, but early postoperative statin discontinuation 
was associated with increased in-hospital mortality (Collard 
et al 2006).
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A recent meta-analysis of 12 retrospective and 3 
prospective trials with a total of 223,010 patients and showed 
that preoperative statin therapy was associated with 38% and 
59% reduction in overall mortality after cardiac and vascular 
surgery (Hindler et al 2006a). In another meta-analysis of 
thirty-one randomized studies that compared a statin with 
placebo or with another statin, statin therapy was associated 
with a reduced relative risk of all cause mortality, cardiovas-
cular mortality, and fatal myocardial infarction, in patients 
with cardiovascular disease (Ward et al 2007). However, the 
potential beneﬁ t of statins for low-risk populations is less 
clear, especially as there may be poor long-term compliance 
in asymptomatic younger patients.
Statins may also be an effective treatment for sepsis as a 
result of increased expression of endothelial nitric oxide syn-
thase, in conjunction with down-regulation of inducible nitric 
oxide synthase (McGown and Brookes 2007). Combined, this 
results in an increase in physiological concentrations of nitric 
oxide, thus restoring endothelial function (Mason et al 2004; 
Tousoulis et al 2006). Laboratory studies have suggested that 
enhancement of endothelial nitric oxide synthase activity 
during sepsis may lead to restoration of microvascular tone, 
maintenance of microvascular integrity, and inhibition of 
cell adhesion molecules (Merx et al 2005; Xenos et al 2005). 
Other pleiotropic effects, including antioxidant activity and 
alterations in the development of vascular atherosclerosis, 
may also contribute to the beneﬁ cial effects of statins in 
this setting.
Timing
It is likely that many, if not all, patients undergoing vascular 
surgery could beneﬁ t from statin therapy and surgeons and 
anesthetists should be alerted to the importance of early 
identiﬁ cation of patients and initiation of statins, as the 
run-in time may affect perioperative cardiovascular outcome 
(Poldermans et al 2003; Durazzo et al 2004). The timing of 
initiation of statin therapy with respect to noncardiac surgery 
is yet to be deﬁ ned, as there is no clear guideline on when 
the drugs should be started. Four weeks should allow time 
for a maximal clinical effect and identiﬁ cation of efﬁ cacy 
(lipid lowering) or side effects (rhabdomyolysis or raised 
liver enzymes) (Poldermans et al 2003). Interestingly no 
increased incidence of adverse effects has been reported 
in these trials of patients receiving perioperative statins 
(Landesberg et al 2003; Poldermans et al 2003). There was 
no statistical difference between postoperative creatine 
kinase levels between statin users and nonusers (Schouten 
et al 2005).
Postoperatively, all patients in whom long-term statin 
therapy is indicated should continue their therapy and any 
patient who has an acute coronary event postoperatively 
and is not on statin therapy should be considered for 
treatment initiation as soon as possible (Spencer et al 2004). 
Discontinuation of statin therapy after major vascular 
surgery is associated with an increased postoperative cardiac 
risk, suggesting that statin therapy should be continued or 
resumed early postoperatively (Le Manach et al 2007). 
It would be reasonable to continue statins for at least 72 
hours postoperatively as this is the time period most likely 
to be associated with an acute coronary event (Badner et al 
1998). Temporarily discontinuing therapy for a day appears 
to be safe (Schouten et al 2005), but high-risk patients are 
probably at increased risk after three days (Heeschen et al 
2003). It is likely that continued statin administration will 
improve outcome further, as in patients who experience acute 
coronary syndromes, the outcome continues to improve with 
prolonged statin administration (Eagle et al 1997; Aronow 
et al 2001), and vascular patients probably beneﬁ t from 
long-term statin therapy anyway (Newby and Nimmo 2004; 
Feringa et al 2006).
Conclusion
There is growing evidence in the world literature to suggest 
that perioperative statin therapy is cost-effective in reducing 
morbidity and mortality in elective vascular surgery. In a 
pharmaco-economic analysis of two prospective studies 
examining the utility of statins in the perioperative period 
in patients undergoing major vascular surgery, Biccard and 
colleagues (2005) showed the number-needed-to-treat to 
prevent an adverse cardiac event was ﬁ fteen. Statins may be 
under-prescribed in vascular surgery patients, especially since 
many of them have clinically occult cardiac ischemia.
Despite a number of interesting potential beneﬁ ts and a 
good safety proﬁ le, there is still a lack of large multicenter 
level I evidence to support the routine use of statins dur-
ing noncardiac surgery, and most of the evidence is from 
retrospective cohort studies (Bolsin et al 2007). Although 
arguments based on biologic plausibility, cohort series, 
small randomized trials and extrapolation from nonsurgical 
cohorts may be misleading, there is already overwhelming 
evidence of efﬁ cacy. A large multi-centre randomized control 
trial on perioperative statin use may be difﬁ cult to conduct 
as there is overwhelming evidence to suggest that statins 
have a beneﬁ cial cardiovascular protective effect, whether 
the patient is undergoing surgery or not. Some authors may 
consider it unethical to with-hold statin treatment to conduct 
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such a trial. Others have shown that in order to reduce the 
perioperative risk of myocardial events by 25%, at least 6000 
patients would need to be recruited for such a study (Kapoor 
et al 2006). Up to now, there is no consensus to support a role 
for the routine administration in patients without established 
coronary artery disease undergoing noncardiac surgery; 
although some have suggested that perioperative statin 
therapy for patients undergoing vascular surgery may present 
the most cost-effective use of statin therapy yet described 
(Biccard et al 2005). Rather to examine the perioperative 
use of statin, future trials may be aimed at determining the 
optimal duration and dosage of perioperative statin therapy 
(Paraskevas et al 2006).
References
Abbruzzese TA, Havens J, Belkin M, et al. 2004. Statin therapy is associ-
ated with improved patency of autogenous infrainguinal bypass grafts. 
J Vasc Surg, 39:1178–85.
Abrams J. 2005. Clinical practice. Chronic stable angina. N Engl J Med, 
352:2524–33.
Adesanya AO, de Lemos JA, Greilich NB, et al. 2006. Management of 
perioperative myocardial infarction in noncardiac surgical patients. 
Chest, 130:584–96.
ALLHAT. 2002. Major outcomes in moderately hypercholesterolemic, 
hypertensive patients randomized to pravastatin vs usual care: the 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart 
Attack Trial (ALLHAT-LLT). JAMA, 288:2998–3007.
Aronow HD, Topol EJ, Roe MT, et al. 2001. Effect of lipid-lowering therapy 
on early mortality after acute coronary syndromes: an observational 
study. Lancet, 357:1063–8.
Ashen MD, Blumenthal RS. 2005. Clinical practice. Low HDL cholesterol 
levels. N Engl J Med, 353:1252–60.
Ashton CM, Petersen NJ, Wray NP, et al. 1993. The incidence of periopera-
tive myocardial infarction in men undergoing noncardiac surgery. Ann 
Intern Med, 118:504–10.
Badner NH, Knill RL, Brown JE, et al. 1998. Myocardial infarction after 
noncardiac surgery. Anesthesiology, 88:572–8.
Bayly PJM, Matthews JNS, Dobson PM. et al. 2001. In-hospital mortality 
from abdominal aortic surgery in Great Britain and Ireland: Vascular 
Anaesthesia Society audit. BJS, 88:687–92.
Biccard BM, Sear JW, Foëx P. 2005. The pharmaco-economics of peri-
operative statin therapy. Anaesthesia, 60:1059–63.
Boden WE, O’Rourke RA, Teo KK, et al. 2007. COURAGE Trial Research 
Group. Optimal medical therapy with or without PCI for stable coronary 
disease. N Engl J Med, 356:1503–16.
Bolsin S, Colson M, Conroy M. 2007. Beta-blockers and statins in non-
cardiac surgery. BMJ, 334:1283–4.
Boushra NN, Muntazar M. 2006. Review article: The role of statins in reduc-
ing perioperative cardiac risk: Physiologic and clinical perspectives. 
Can J Anaesth, 53:1126–47.
Chan AW, Bhatt DL, Chew DP, et al. 2002. Early and sustained survival 
beneﬁ t associated with statin therapy at the time of percutaneous coro-
nary intervention. Circulation, 105:691–6.
Cohen MC, Aretz TH. 1999. Histological analysis of coronary artery 
lesions in fatal postoperative myocardial infarction. Cardiovasc Pathol, 
8:133–9.
Collard CD, Body SC, Shernan SK, et al; Multicenter Study of Perioperative 
Ischemia (MCSPI) Research Group, Inc; Ischemia Research and Educa-
tion Foundation (IREF) Investigators. 2006. Preoperative statin therapy 
is associated with reduced cardiac mortality after coronary artery bypass 
graft surgery. J Thorac Cardiovasc Surg, 132:392–400.
Devereaux PJ, Beattie WS, Choi PT, et al. 2005. How strong is the evidence 
for the use of perioperative beta blockers in non-cardiac surgery? 
Systematic review and meta-analysis of randomised controlled trials. 
BMJ, 331:313–21.
Downs JR, Clearﬁ eld M, Weis S, et al. 1998. Primary prevention of acute 
coronary events with lovastatin in men and women with average choles-
terol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary 
Atherosclerosis Prevention Study. JAMA, 279:1615–22.
Dunkelgrun M, Schouten O, Feringa HH, et al. 2006. Beneﬁ cial effects of 
statins on perioperative cardiovascular outcome. Curr Opin Anaesthe-
siol, 19:418–22.
Durazzo AE, Machado FS, Ikeoka DT, et al. 2004. Reduction in cardio-
vascular events after vascular surgery with atorvastatin: a randomized 
trial. J Vasc Surg, 39:967–75.
Eagle KA, Rihal CS, Mickel MC, et al. 1997. Cardiac risk of noncardiac 
surgery: influence of coronary disease and type of surgery in 
3,368 operations. CASS Investigators and University of Michigan 
Heart Care Program. Coronary Artery Surgery Study. Circulation, 
96:1882–7.
Eisenberg DA. 1998. Cholesterol lowering in the management of coronary 
artery disease: the clinical implications of recent trials. Am J Med, 
104(2A):2S–5S.
Erl W, Hristov M, Neureuter M, et al. 2003. HMG-CoA reductase inhibitors 
induce apoptosis in neointima-derived vascular smooth muscle cells, 
Atherosclerosis, 169:251–8.
Feringa HH, Bax JJ, Schouten O, et al. 2006. Protecting the heart with 
cardiac medication in patients with left ventricular dysfunction under-
going major noncardiac vascular surgery. Semin Cardiothorac Vasc 
Anesth, 10:25–31.
Feringa HH, Karagiannis SE, van Waning VH, et al. 2007. The effect of 
intensiﬁ ed lipid-lowering therapy on long-term prognosis in patients 
with peripheral arterial disease. J Vasc Surg, 45:936–43.
Gibson CM, Ciaglo LN, Southard MC, et al. 2007. Diagnostic and prognostic 
value of ambulatory ECG (Holter) monitoring in patients with coronary 
heart disease: a review. J Thromb Thrombolysis, 23:135–45.
Grundy SM. 1988. HMG-CoA reductase inhibitors for treatment of hyper-
cholesterolemia. N Engl J Med, 319:24–33.
Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart 
Protection Study of antioxidant vitamin supplementation in 20,536 
high-risk individuals: a randomised placebo-controlled trial. Lancet 
2002; 360:23–33.
Heeschen C, Hamm CW, Laufs U, et al. 2003. Withdrawal of statins in 
patients with acute coronary syndromes. Circulation, 107:e27.
Henke PK, Blackburn S, Proctor MC, et al. 2004. Patients undergoing 
infrainguinal bypass to treat atheroscle-rotic vascular disease are 
underprescribed cardio-protective medications: effect on graft patency, 
limb salvage, and mortality. J Vasc Surg, 39:357–65.
Hindler K, Eltzschig HK, Fox AA, et al. 2006a. Inﬂ uence of statins on 
perioperative outcomes. J Cardiothorac Vasc Anesth, 20:251–8.
Hindler K, Shaw AD, Samuels J, et al. 2006b. Improved postoperative 
outcomes associated with preoperative statin therapy. Anesthesiology, 
105:1260–72.
Imparato AM, Riles TS, Mintzer R, et al. 1983. The importance of hemor-
rhage in the relationship between gross morphologic characteristics 
and cerebral symptoms in 376 carotid artery plaques, Ann Surg, 
197:195–203.
Kapoor AS, Kanji H, Buckingham J, et al. 2006. Strength of evidence for 
perioperative use of statins to reduce cardiovascular risk: systematic 
review of controlled studies. BMJ, 333:1149.
Kertai MD, Boersma E, Westerhout CM, et al. 2004. A combination of 
statins and beta-blockers is independently associated with a reduction 
in the incidence of perioperative mortality and nonfatal myocardial 
infarction in patients undergoing abdominal aortic aneurysm surgery. 
Eur J Vasc Endovasc Surg, 28:343–52.
Kertai MD, Bogar L, Gal J, et al. 2006. Pre-operative coronary revascu-
larization: an optimal therapy for high-risk vascular surgery patients? 
Acta Anaesthesiol Scand, 50:816–27.
Vascular Health and Risk Management 2008:4(1) 81
Perioperative use of statins in noncardiac surgery
Khanal S, Attallah N, Smith DE, et al. 2005. Statin therapy reduces 
contrast-induced nephropathy: an analysis of contemporary percutane-
ous interventions. Am J Med, 118:843–9.
Koutouzis M, Nomikos A, Nikolidakis S, et al. 2007. Statin treated patients 
have reduced intraplaque angiogenesis in carotid endarterectomy 
specimens. Atherosclerosis, 192:457–63.
LaMuraglia GM, Stoner MC, Brewster DC, et al. 2005. Determinants of 
carotid endarterectomy anatomic durability: effects of serum lipids and 
lipid-lowering drugs. J Vasc Surg, 41:762–8.
Landesberg G, Mosseri M, Wolf YG, et al. 2003. Preoperative thallium 
scanning, selective coronary revascularization, and long-term survival 
after major vascular surgery. Circulaton, 108:177–83.
Le Manach Y, Godet G, Coriat P, et al. 2007. The impact of postoperative 
discontinuation or continuation of chronic statin therapy on cardiac 
outcome after major vascular surgery. Anesth Analg, 104:1326–33.
Liao JK. 2005. Clinical implications for statin pleiotropy. Curr Opin 
Lipidol, 16:624–9.
Libby P. 2002. Inﬂ ammation in atherosclerosis. Nature, 420:868–74.
Lindenauer PK, Pekow P, Wang K, et al. 2004. Lipid-lowering therapy 
and in-hospital mortality following major noncardiac surgery. JAMA, 
291:2092–9.
LIPID Study Group. 1998. Prevention of cardiovascular events and death 
with pravastatin in patients with coronary heart disease and a broad 
range of initial cholesterol levels. The Long-Term Intervention with 
Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 
339:1349–57.
Mangano DT, Browner W, Hollenberg M, et al; for the Study of Periop-
erative Ischemia Research Group. 1992. Long-term cardiac prognosis 
following noncardiac surgery. JAMA, 268:233–9.
Mason RP, Walter MF, Jacob RF. 2004. Effects of HMG-CoA reductase 
inhibitors on endothelial function: role of microdomains and oxidative 
stress. Circulation, 109(21 Suppl 1):II34-II41.
McCarthy MJ, Loftus IM, Thompson MM, et al. 1999. Angiogenesis and the 
atherosclerotic carotid plaque: an association between symptomatology 
and plaque morphology. J Vasc Surg, 30:261–8.
McGown CC, Brookes ZL. 2007. Beneﬁ cial effects of statins on the micro-
circulation during sepsis: the role of nitric oxide. Br J Anaesthsia, 
98:163–75.
Merx MW, Liehn EA, Graf J, et al. 2005. Statin treatment after onset of sepsis 
in a murine model improves survival. Circulation, 112:117–24.
Newby DE, Nimmo AF. 2004. Prevention of cardiac complications of non-
cardiac surgery: stenosis and thrombosis. Br J Anaesth, 92:628–32.
Noordzij PG, Poldermans D, Schouten O, et al. 2007. Beta-blockers and 
statins are individually associated with reduced mortality in patients 
undergoing noncardiac, nonvascular surgery. Coron Artery Dis, 
8:67–72.
O’Neil-Callahan K, Katsimaglis G, Tepper MR, et al. 2005. Statins decrease 
perioperative cardiac complications in patients undergoing noncardiac 
vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) 
study. J Am Coll Cardiol, 45:336–42.
Paraskevas KI, Liapis CD, Hamilton G, et al. 2006. Can statins reduce peri-
operative morbidity and mortality in patients undergoing non-cardiac 
vascular surgery? Eur J Vasc Endovasc Surg, 32:286–93.
Pasternack PF, Grossi EA, Baumann FG, et al. 1989. The value of silent 
myocardial ischemia monitoring in the prediction of perioperative myo-
cardial infarction in patients undergoing peripheral vascular surgery. 
J Vasc Surg, 10:617–25.
Poldermans D, Bax JJ, Kertai MD, et al. 2003. Statins are associated with 
a reduced incidence of perioperative mortality in patients undergoing 
major noncardiac vascular surgery. Circulation, 107:1848–51.
Poldermans D, Bax JJ, Kertai MD, et al. 2003. Statins are associated with 
a reduced incidence of perioperative mortality in patients undergoing 
major non-cardiac vascular surgery. Circulation, 107:1848–51.
Poldermans D, Boersma E, Bax JJ, et al. 2001. Correlation of location 
of acute myocardial infarct after noncardiac vascular surgery with 
preoperative dobutamine echocardiographic ﬁ ndings. Am J Cardiol, 
88:1413–14.
Poldermans D, Schouten O, Vidakovic R, et al.; DECREASE Study Group. 
2007. A clinical randomized trial to evaluate the safety of a noninvasive 
approach in high-risk patients undergoing major vascular surgery: the 
DECREASE-V Pilot Study. J Am Coll Cardiol, 49:1763–9.
Priebe HJ. 2004. Triggers of perioperative myocardial ischaemia and infarc-
tion. Br J Anaesth, 93:9–20.
[4S] Scandinavian Simvastatin Study Group. 1994. Randomised trial of 
cholesterol lowering in 4444 patients with coronary heart disease: the 
Scandinavian Simvastatin Survival Study (4S). Lancet, 344:1383–9.
Sacks FM, Pfeffer MA, Moye LA, et al. 1996. The effect of pravastatin on 
coronary events after myocardial infarction in patients with average 
cholesterol levels. Cholesterol and Recurrent Events Trial investigators. 
N Engl J Med, 335:1001–9.
Schouten O, Bax JJ, Dunkelgrun M, et al. 2006a. Statins for the preven-
tion of perioperative cardiovascular complications in vascular surgery. 
J Vasc Surg, 44:419–24.
Schouten O, Kertai MD, Bax JJ, et al. 2005. Safety of perioperative statin 
use in high-risk patients undergoing major vascular surgery. Am J 
Cardiology, 95:658–60.
Schouten O, Kok NF, Boersma E, et al. 2006b. Effects of statins on renal 
function after aortic cross clamping during major vascular surgery. Am 
J Cardiol, 97:1383–5.
Schouten O, van Laanen JHH, Boersma E, et al. 2006c. Statins are associ-
ated with a reduced infrarenal abdominal aortic aneurysm growth. Eur 
J Vasc Endovasc Surg, 32:21–6.
Shepherd J, Blauw GJ, Murphy MB, et al. 2002. Pravastatin in elderly indi-
viduals at risk of vascular disease (PROSPER): a randomised controlled 
trial. Lancet, 360:1623–30.
Spencer FA, Allegrone J, Goldberg RJ, et al; GRACE Investigators. 2004. 
Association of statin therapy with outcomes of acute coronary syn-
dromes: the GRACE study. Ann Intern Med, 140:857–66.
Takemoto M, Liao JK. 2001. Pleiotropic effects of 3-hydroxy-3-methyl-
glutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc 
Biol, 21:1712–19.
Tousoulis D, Antoniades C, Koumallos N, et al. 2006. Novel therapies 
targeting vascular endothelium. Endothelium, 13:411–21.
Ward RP, Leeper NJ, Kirkpatrick JN, et al. 2005. The effect of preopera-
tive statin therapy on cardiovascular outcomes in patients undergoing 
infrainguinal vascular surgery. Int J Cardiol, 104:264–8.
Ward S, Lloyd Jones M, Pandor A, et al. 2007. A systematic review and 
economic evaluation of statins for the prevention of coronary events. 
Health Technol Assess, 11:1–178.
Wong GTC, Irwin MG. 2007. Contrast induced nephropathy. Br J Anaesth, 
99:474–83.
Xenos ES, Stevens SL, Freeman MB, et al. 2005. Nitric oxide mediates the 
effect of ﬂ uvastatin on intercellular adhesion molecule-1 and platelet 
endothelial cell adhesion molecule-1 expression on human endothelial 
cells. Ann Vasc Surg, 19:386–92.
Zaman AG, Helft G, Worthley SG, et al. 2000. The role of plaque rupture and 
thrombosis in coronary artery disease. Atherosclerosis, 149:251–66.
